Number of Prescription Medications and Overall Survival in Metastatic Castrate-Resistant Prostate Cancer
Conclusions: The number and type of medications were independently associated with survival in patients undergoing treatment for mCRPC. With new therapies for treatment of advanced prostate cancer, patients are living longer, which increases the need for better understanding of the impact of comorbi...
Saved in:
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2024-01-01
|
| Series: | Prostate Cancer |
| Online Access: | http://dx.doi.org/10.1155/proc/6863066 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850105013092745216 |
|---|---|
| author | Carley R. Pickett Daniel B. Eaton Krishny Karunanandaa Emily Cybulla Brendan T. Heiden Su-Hsin Chang Yan Yan Melanie P. Subramanian Varun Puri Martin W. Schoen |
| author_facet | Carley R. Pickett Daniel B. Eaton Krishny Karunanandaa Emily Cybulla Brendan T. Heiden Su-Hsin Chang Yan Yan Melanie P. Subramanian Varun Puri Martin W. Schoen |
| author_sort | Carley R. Pickett |
| collection | DOAJ |
| description | Conclusions: The number and type of medications were independently associated with survival in patients undergoing treatment for mCRPC. With new therapies for treatment of advanced prostate cancer, patients are living longer, which increases the need for better understanding of the impact of comorbid diseases. Simple methods to assess disease burden and prognosticate survival have the potential to guide treatment decisions and improve the quality of life in this patient population. |
| format | Article |
| id | doaj-art-e0999f37ca4f48bc84c882cd98196b94 |
| institution | DOAJ |
| issn | 2090-312X |
| language | English |
| publishDate | 2024-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Prostate Cancer |
| spelling | doaj-art-e0999f37ca4f48bc84c882cd98196b942025-08-20T02:39:12ZengWileyProstate Cancer2090-312X2024-01-01202410.1155/proc/6863066Number of Prescription Medications and Overall Survival in Metastatic Castrate-Resistant Prostate CancerCarley R. Pickett0Daniel B. Eaton1Krishny Karunanandaa2Emily Cybulla3Brendan T. Heiden4Su-Hsin Chang5Yan Yan6Melanie P. Subramanian7Varun Puri8Martin W. Schoen9Division of Hematology and Medical OncologyDivision of Hematology and Medical OncologyDivision of Hematology and Medical OncologyDivision of Hematology and Medical OncologyDivision of Cardiothoracic SurgeryDivision of Cardiothoracic SurgeryDivision of Cardiothoracic SurgeryDivision of Cardiothoracic SurgeryDivision of Hematology and Medical OncologyDivision of Hematology and Medical OncologyConclusions: The number and type of medications were independently associated with survival in patients undergoing treatment for mCRPC. With new therapies for treatment of advanced prostate cancer, patients are living longer, which increases the need for better understanding of the impact of comorbid diseases. Simple methods to assess disease burden and prognosticate survival have the potential to guide treatment decisions and improve the quality of life in this patient population.http://dx.doi.org/10.1155/proc/6863066 |
| spellingShingle | Carley R. Pickett Daniel B. Eaton Krishny Karunanandaa Emily Cybulla Brendan T. Heiden Su-Hsin Chang Yan Yan Melanie P. Subramanian Varun Puri Martin W. Schoen Number of Prescription Medications and Overall Survival in Metastatic Castrate-Resistant Prostate Cancer Prostate Cancer |
| title | Number of Prescription Medications and Overall Survival in Metastatic Castrate-Resistant Prostate Cancer |
| title_full | Number of Prescription Medications and Overall Survival in Metastatic Castrate-Resistant Prostate Cancer |
| title_fullStr | Number of Prescription Medications and Overall Survival in Metastatic Castrate-Resistant Prostate Cancer |
| title_full_unstemmed | Number of Prescription Medications and Overall Survival in Metastatic Castrate-Resistant Prostate Cancer |
| title_short | Number of Prescription Medications and Overall Survival in Metastatic Castrate-Resistant Prostate Cancer |
| title_sort | number of prescription medications and overall survival in metastatic castrate resistant prostate cancer |
| url | http://dx.doi.org/10.1155/proc/6863066 |
| work_keys_str_mv | AT carleyrpickett numberofprescriptionmedicationsandoverallsurvivalinmetastaticcastrateresistantprostatecancer AT danielbeaton numberofprescriptionmedicationsandoverallsurvivalinmetastaticcastrateresistantprostatecancer AT krishnykarunanandaa numberofprescriptionmedicationsandoverallsurvivalinmetastaticcastrateresistantprostatecancer AT emilycybulla numberofprescriptionmedicationsandoverallsurvivalinmetastaticcastrateresistantprostatecancer AT brendantheiden numberofprescriptionmedicationsandoverallsurvivalinmetastaticcastrateresistantprostatecancer AT suhsinchang numberofprescriptionmedicationsandoverallsurvivalinmetastaticcastrateresistantprostatecancer AT yanyan numberofprescriptionmedicationsandoverallsurvivalinmetastaticcastrateresistantprostatecancer AT melaniepsubramanian numberofprescriptionmedicationsandoverallsurvivalinmetastaticcastrateresistantprostatecancer AT varunpuri numberofprescriptionmedicationsandoverallsurvivalinmetastaticcastrateresistantprostatecancer AT martinwschoen numberofprescriptionmedicationsandoverallsurvivalinmetastaticcastrateresistantprostatecancer |